Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France

PLoS One. 2020 Oct 15;15(10):e0240782. doi: 10.1371/journal.pone.0240782. eCollection 2020.

Abstract

Background: To fight the COVID-19 pandemic, lockdown has been decreed in many countries worldwide. The impact of pregnancy as a severity risk factor is still debated, but strict lockdown measures have been recommended for pregnant women.

Objectives: To evaluate the impact of the COVID-19 pandemic and lockdown on the seroprevalence and circulation of SARS-CoV-2 in a maternity ward in an area that has been significantly affected by the virus.

Study design: Prospective study at the Antoine Béclère Hospital maternity ward (Paris area, France) from May 4 (one week before the end of lockdown) to May 31, 2020 (three weeks after the end of lockdown). All patients admitted to the delivery room during this period were offered a SARS-CoV-2 serology test as well concomitant SARS-CoV-2 RT-PCR on one nasopharyngeal sample.

Results: A total of 249 women were included. Seroprevalence of SARS-CoV-2 was 8%. The RT-PCR positive rate was 0.5%. 47.4% of the SARS-CoV-2-IgG-positive pregnant women never experienced any symptoms. A history of symptoms during the epidemic, such as fever (15.8%), myalgia (36.8%) and anosmia (31.6%), was suggestive of previous infection.

Conclusions: Three weeks after the end of French lockdown, SARS-CoV-2 infections were scarce in our region. A very high proportion of SARS-CoV-2-IgG-negative pregnant women, which is comparable to that of the general population, must be taken into consideration in the event of a resurgence of the pandemic. The traces of a past active circulation of the virus in this fragile population during the spring wave should encourage public health authorities to take specific measures for this independent at-risk group, in order to reduce viral circulation in pregnant patients.

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Betacoronavirus / genetics*
  • Betacoronavirus / immunology*
  • COVID-19
  • COVID-19 Testing
  • COVID-19 Vaccines
  • Clinical Laboratory Techniques*
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / microbiology
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / virology
  • Female
  • Humans
  • Immunoglobulin G / blood
  • Pandemics / prevention & control
  • Paris / epidemiology
  • Parturition*
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / virology
  • Pregnancy
  • Pregnancy Complications, Infectious / epidemiology*
  • Pregnancy Complications, Infectious / virology
  • Prospective Studies
  • Quarantine / methods
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • SARS-CoV-2
  • Seroepidemiologic Studies
  • Serologic Tests

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Covid-19 aAPC vaccine
  • Immunoglobulin G

Grants and funding

The authors received no specific funding for this work.